Modeling cancer patient populations in mice: complex genetic and environmental factors

Area of Science:

• Oncology
• Pharmacogenomics
• Translational Medicine

Background:

• Individual genetic differences influence cancer risk and response to cancer drugs.
• Existing mouse models for tumorigenesis and drug testing do not accurately predict clinical trial success.
• Cancer is a complex disease influenced by patient heterogeneity.

Purpose of the Study:

• To highlight the limitations of current preclinical cancer models.
• To advocate for the development of more sophisticated models for drug testing.
• To improve the prediction of therapeutic efficacy and toxicity in diverse patient populations.

Main Methods:

• Review of current understanding of genetic influences on cancer.
• Analysis of the predictive accuracy of existing mouse models in drug development.
• Conceptual proposal for advanced cancer modeling.

Main Results:

• Current mouse models inadequately predict human responses to cancer therapies.
• Genetic heterogeneity in patients is a critical factor in treatment outcomes.
• Sophisticated models are needed to bridge the gap between preclinical research and clinical application.

Conclusions:

• Advanced, patient-centric cancer models are essential for accurate drug development.
• Improved models will enhance the identification of patients benefiting from specific therapies.
• Predictive models can mitigate risks of drug-induced toxicities in clinical settings.